Boothbay Fund Management, LLC Janux Therapeutics, Inc. Transaction History
Boothbay Fund Management, LLC
- $3.27 Billion
- Q4 2024
A detailed history of Boothbay Fund Management, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 26,897 shares of JANX stock, worth $875,497. This represents 0.04% of its overall portfolio holdings.
Number of Shares
26,897
Previous 106,500
74.74%
Holding current value
$875,497
Previous $4.84 Million
70.24%
% of portfolio
0.04%
Previous 0.13%
Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
229Shares Held
54.7MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$337 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$116 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$114 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$99.7 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$76.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.36B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...